To determine the potential of anti-GBM therapies targeting the DRD3 pathway, we first tested the GBM growth inhibitory capacity of a panel of 9 novel, selective DRD3-selective antagonists [29, 30]. The gene discussed is DRD3; the disease is glioblastoma.